Miranda Elaine Silva, Pinto Cláudia Du Bocage Santos, dos Reis André Luis de Almeida, Emmerick Isabel Cristina Martins, Campos Mônica Rodrigues, Luiza Vera Lucia, Osorio-de-Castro Claudia Garcia Serpa
Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.
Cad Saude Publica. 2009 Oct;25(10):2147-58. doi: 10.1590/s0102-311x2009001000006.
A study to identify availability and prices of medicines, according to type of provider, was conducted in the five regions of Brazil. A list of medicines to treat prevalent diseases was investigated, using the medicines price methodology developed by the World Health Organization and Health Action International, adapted for Brazil. In the public sector, bioequivalent (vis-à-vis reference brand) generics are less available than multisource products. For most medicines (71.4%), the availability of bioequivalent generics was less than 10%. In the private sector, the average number of different bioequivalent generic versions in the outlets was far smaller than the number of versions on the market. There was a positive correlation between the number of generics on the market, or those found at outlets, and the price variation in bioequivalent generic products, in relation to the maximum consumer price. It is estimated that price competition is occurring among bioequivalent generic drugs and between them and multisource products for the same substance, but not with reference brands.
在巴西的五个地区开展了一项研究，旨在根据供应商类型确定药品的可获得性和价格。研究使用了世界卫生组织和国际卫生行动组织开发并针对巴西进行调整的药品价格方法，调查了治疗常见疾病的药品清单。在公共部门，生物等效（相对于参比品牌）仿制药的可获得性低于多来源产品。对于大多数药品（71.4%），生物等效仿制药的可获得性低于10%。在私营部门，各销售点不同生物等效仿制药版本的平均数量远低于市场上的版本数量。市场上或销售点发现的仿制药数量与生物等效仿制药产品相对于最高消费者价格的价格变化之间存在正相关关系。据估计，生物等效仿制药之间以及它们与同一物质的多来源产品之间存在价格竞争，但与参比品牌不存在价格竞争。
